New Alert: (NASDAQ: XXII) 22nd Century Group, Inc.- Game-Changer In Nicotine Reduction Space

New Alert: 22nd Century Group, Inc. (NASDAQ: XXII) Game-Changer In Nicotine Reduction Space 10XProTrader Member, This is Kevin Vander with "10XProTrader", we have a brand new profile for you. It's, [22nd Century Group, Inc. (NASDAQ: XXII)]( We've never shied away from introducing companies that do things differently from their competitor herd. In fact, we embrace those innovators, especially when they present compelling investment opportunities. Today's profile this morning checks both those boxes. And in an industry with billions in revenue dollars up for grabs, this current $0.25 stock may be presenting a value proposition that's too attractive to ignore. And for smokers especially, with XXII telling them they don't need to quit smoking altogether, but instead take control of their nicotine intake and make healthier choices. About 22nd Century Group, Inc. (NASDAQ: XXII) 22nd Century Group, Inc. (Nasdaq: XXII) is a next-generation plant biotechnology company, focused on improving human health through plant science. Using their breakthrough, patent-protected IP to control nicotine biosynthesis in the tobacco plant, they have developed the first market-ready, reduced nicotine content (RNC) tobacco plants and cigarettes containing 95% less nicotine. They received the first and only FDA MRTP authorization for a combustible cigarette in December 2021. The sole function of their cigarettes is to make it easier to reduce the number of cigarettes smoked. In tobacco, 22nd Century employs a unique and innovative platform of modern plant breeding technologies, including genetic engineering, gene-editing, and molecular breeding, to deliver healthier solutions for pressing issues. They create new, proprietary plants with select alkaloid, terpenoid, and flavonoid profiles, improved yields, and valuable agronomic traits for the life science and consumer products industries. Learn more at [xxiicentury.com]( Rather than fight that trend, they've done something better by developing a product line that gives choices back to the consumer and, at the same time, pioneers a movement that is reshaping the tobacco industry. Now, XXII isn't saying that all of a sudden, nicotine is good. Far from it. But they are serving up a product option, its innovative VLN® (Very Low Nicotine) cigarettes, that can do more than appease those wanting nicotine- they're developing a whole new category that could also serve investor appetites craving innovative and revolutionary growth stock companies.  A game-changer in the reduced harm landscape... Its innovative VLN® cigarettes empower smokers to reduce nicotine consumption without sacrificing the smoking experience they know. That difference is a competitive advantage. And it's not just another nicotine delivery system; it's giving smokers the ability to make informed decisions about their nicotine intake. The value driver in its mission to create market and shareholder value is the FDA-approved VLN® cigarette, which contains 95% less nicotine than traditional cigarettes.  Here's the more important consideration from an investor perspective- XXII's VLN® cigarette is uniquely positioned as the only combustible cigarette authorized to be marketed as a Modified Risk Tobacco Product, carrying the powerful message that it "Helps You Smoke Less®." Learn more about VLN® at [tryvln.com](. 22nd Century Group, Inc. may be paving the way for a new standard in smoking that reflects progress, not replacement. If successful, this sub-dollar company could be behind a shift that could disrupt the entire tobacco landscape. That mission is in progress, evidenced by XXII's vision translating to real market traction. According to updates, sales of VLN® have exceeded expectations in many of the test markets established in 2023, leading XXII to expand its sales and marketing operations. Currently, VLN® is available in over 5,000 stores across 26 states, but that's just the beginning. [The first cigarette that helps you smoke less.]( VLN® is an FDA authorized, new-to-market product with 95% less nicotine than traditional cigarettes. This innovative product aids in reducing your smoking by considerably lowering your nicotine consumption. - First of Its Kind: The only tobacco cigarette authorized by the FDA to help you smoke less, VLN® offers an entirely new approach. - A Familiar Smoking Experience: VLN® cigarettes smoke, taste, and smell like what you're used to, just with less nicotine. VLN® and Helps You Smoke Less® are registered trademarks of 22nd Century Limited LLC. [tryvln.com](  All of the above contributes to an evidence-based case for why XXII needs to be considered for a growth stock portfolio. Remember, XXII's VLN® cigarettes don't deprive smokers of satisfaction. Instead, they allow smokers to enjoy a smoking routine with the added benefit of significantly reduced nicotine exposure. That delivers more than a win-win proposition—it also fills a gap in the harm-reduction nicotine market ripe for the taking. And that's exactly what XXII is in the process of doing. With its VLN® a trailblazer in the space, similar to early category creators in other industries that changed consumer behavior by meeting them where they are, not where companies wanted them to be. If you missed some of my recent big "10x Alerts"  I strongly suggest you get ready for our explosive new breakout alert... Because, you don't want to miss another winner with tremendous upside potential! Pay very close attention to your email inbox, your next alert is just around the corner. Yours for greater gains, Kevin Vander Publisher, 10XProTrader.com Investment Research Sources: [( [( [( [( [( [( [( [( [( [www.stocktitan.net/news/XXII/22nd-century-updates-strategic-growth-initiatives-for-h5vt2iq9hh35.html#:~:text=22nd%20Century%20Group%20plans%20to,their%2095%25%20less%20nicotine%20tobacco.]( You are receiving this e-mail as part of your subscription to 10XProTrader. Please do not reply to this e-mail as this address is not monitored. Our Customer Service team is available Monday - Friday between 9:00 AM and 5:00 PM ET. © 2024 10XProTrader.com. All Rights Reserved. Nothing in this email should be considered personalized financial advice. Although our employees may answer your general customer service questions, they are not licensed under securities laws to address your particular inves∙tment situation. N∙o communication by our employees to you should be deemed as personalized financial advice. We expressly forbid our writers from having a financial interest in any security recommended to our readers, prior or during our reporting on the company. © 2024 10XProTrader.com, All Rights Reserved. 10XProTrader is a financial publisher that does not offer any personal financial advice or advocate the purchase or sale of any security or inve∙stment for any specific individual. This communication is a paid a∙dvertisement. 10XProTrader.com and/or its subsidiaries and/or affiliates ("Company," "we," or "us") have been compensated $20,000 USD to disseminate this communication. Please note that we do not trade any securities that we profile. We do not hold positions in stocks we profile. We do not accept stock as a form of payment for our profiles. Please review the full disc∙laimer at [( for important information about this advertisement. © 2023 10XProTrader. All rights reserved., 340 Royal Poinciana Way Suite 317, 33480, Palm Beach, United States You may [unsubscribe]( or [change your contact details]( at any time.